Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 9/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SOD3 | P08294 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2504572 | 0.94 | ALOX5 (0.49) | ALOX5GNAO1GNAI3GNAI1MEN1 | |
| SCHEMBL27293688 | 0.94 | ALOX5 (0.41) | ALOX5GNAO1GNAI3GNAI1L3MBTL1 | |
| SCHEMBL27877149 | 0.92 | ALOX5 (0.51) | ALOX5GNAO1GNAI3GNAI1SOD3 | |
| Methylamine SCHEMBL27943477 | 0.88 | ALOX5 (0.49) | ALOX5GNAO1GNAI3GNAI1SOD3 | |
| SCHEMBL1741781 | 0.87 | — | — | |
| Methylamine SCHEMBL27943479 | 0.83 | ALOX5 (0.40) | ALOX5GNAO1GNAI3GNAI1MEN1 | |
| SCHEMBL7022863 | 0.78 | — | — | |
| SCHEMBL13070544 | 0.75 | — | — | |
| SCHEMBL13100975 | 0.73 | — | — | |
| SCHEMBL2009978 | 0.72 | CXCR4 (0.35) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1039283-C | Use of Porphyrins | FMC CORP (US) | 1998-07-29 | — | — | CN | claimed |
| US-5407808-A | Treating tumor with inhibitor of protoporphyrinogen conversion to heme | FMC CORPORATION (US) | 1995-04-18 | — | — | US | claimed |
| US-5298502-A | Exposure to light in presence of oxidase inhibitor | FMC CORPORATION (US) | 1994-03-29 | — | — | US | claimed |
| EP-0447491-B1 | PROTOPORPHYRINOGEN INHIBITORS AND THEIR USE IN COMPOSITIONS FOR DETECTING AND TREATING TUMOURS | FMC CORP (US) | 1993-08-11 | — | — | EP | claimed |
| US-7629318-B2 | Immunosuppressant compounds, methods and uses related thereto | GPC BIOTECH AG (DE) | 2009-12-08 | — | — | US | disclosed |
| US-20060004077-A1 | Immunosuppressant compounds, methods and uses related thereto | GPC BIOTECH AG (DE) | 2006-01-05 | — | — | US | disclosed |
| CN-1166689-C | Purification method of hemoglobin | ض� | 2004-09-15 | — | — | CN | disclosed |
| CN-1308636-A | Purification method of hemoglobin | BIOPURE CORP (US) | 2001-08-15 | — | — | CN | disclosed |
| US-5407808-A | Treating tumor with inhibitor of protoporphyrinogen conversion to heme | FMC CORPORATION (US) | 1995-04-18 | — | — | US | disclosed |
| US-5298502-A | Exposure to light in presence of oxidase inhibitor | FMC CORPORATION (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0447491-B1 | PROTOPORPHYRINOGEN INHIBITORS AND THEIR USE IN COMPOSITIONS FOR DETECTING AND TREATING TUMOURS | FMC CORP (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1991019418-A1 | TREATMENT OF DISEASE | FMC CORPORATION (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0447491-A1 | Protoporphyrinogen inhibitors and their use in compositions for detecting and treating Tumours. | FMC CORP (US) | 1991-09-25 | — | — | EP | disclosed |
| WO-1990006748-A2 | USE OF CERTAIN HERBICIDES IN CANCER TREATMENT AND PRODUCTION OF PROTOPORPHYRIN IX | FMC CORPORATION (US) | 1990-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004077-A1 | Immunosuppressant compounds, methods and uses related thereto | HLA-DRB1, CD74, MICA | ALOX5 87/4885GNAO1 1230/4885GNAI3 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.